SVA Stock UPDATES Sinovac Biotech (SVA) 5.34 10/21/2014 21:3
Post# of 273217
Sinovac to Participate in Jefferies 4th Annual Asia Summit
PR Newswire - Tue Oct 21, 5:06AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will host investor meetings at the Jefferies 4th Annual Asia Summit, to be held at the Island Shangri-La Hotel in Hong Kong on October 29-30, 2014. Please contact your Jefferies institutional sales representative to schedule a meeting with the Company.
SVA: 5.34 (+0.01)
PMT, BPOPM, EXAS, SVA, SGG Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Fri Oct 10, 4:20AM CDT
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Perpetual Energy Inc (NYSE MT), Popular Capital Trust II (NASDAQ:BPOPM), Exact Sciences Corp (NASDAQ:EXAS), Sernova Corp (NASDAQ:SVA), SnipGold Corp (NYSE:SGG) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
SGG: 42.18 (-0.98), PMT: 21.41 (+0.18), EXAS: 24.22 (+0.36), SVA: 5.34 (+0.01), BPOPM: 20.62 (-0.07)
Sinovac Biotech Shares Down 10.5% Since SmarTrend's Sell Call (SVA)
Comtex SmarTrend(R) - Wed Oct 08, 5:08PM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 6 months, Sinovac Biotech has returned 10.54% as of today's recent price of $5.26.
SVA: 5.34 (+0.01)
3 Biotech Stocks Under $10 in Breakout Territory
at The Street - Wed Oct 08, 7:30AM CDT
Keep these under-$10 biotech stocks on your breakout trading radar.
OXGN: 2.03 (+0.11), NVAX: 4.99 (-0.02), SVA: 5.34 (+0.01)
Shares of SVA Down 14.3% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Sep 17, 4:57PM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 14.29% as of today's recent price of $5.04.
SVA: 5.34 (+0.01)
Lorien Health Systems to Roll out SIM(TM) Across its US Facilities
Marketwire - Tue Sep 16, 1:33PM CDT
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to announce that the Company's exclusive US distribution partner, Medline Industries, Inc. ("Medline" , has advised that it has executed an agreement under which it will roll out Simavita's SIM(TM) incontinence assessment and management solution across all of the Skilled Nursing facilities operated by US aged care provider, Lorien Health Systems ("Lorien".)
SV.VN: 0.450 (+0.150), SVA: 5.34 (+0.01)
Lorien Health Systems to Roll Out Simavita's SIM(TM) across Its US Facilities
Business Wire - Tue Sep 16, 8:00AM CDT
--Leading US aged care services provider, Lorien Health Systems to roll out Simavita's SIM(TM) Smart Incontinence Management system across all of its skilled nursing facilities
SV.VN: 0.450 (+0.150), SVA: 5.34 (+0.01)
Simavita Limited: Resignation of Chairman
Marketwire - Fri Sep 12, 11:27AM CDT
Simavita Limited (ASX: SVA) (TSX VENTURE: SV) ("Simavita" or the "Company" announces the decision of the Company's Chairman, Mr. Peter Cook, to resign as a Director of Simavita, with immediate effect.
SV.VN: 0.450 (+0.150), SVA: 5.34 (+0.01)
Tetanus Therapeutics Pipeline Review, H2 2014 - 15 Companies with 29 Drug Profiles
M2 - Tue Sep 09, 6:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/qnddk4/tetanus) has announced the addition of the "Tetanus - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Tetanus, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Tetanus and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GlaxoSmithKline plc - Daiichi Sankyo Company, Limited - Takeda Pharmaceutical Company Limited - Biological E. Limited - Novartis AG - Zydus Cadila Healthcare Limited - Green Cross Corporation - LG Life Sciences, Ltd. - Bharat Biotech International Limited - Sinovac Biotech Ltd. - Serum Institute of India Limited - Indian Immunologicals Limited - Beijing Minhai Biotechnology Co., Ltd - Sanofi Pasteur SA Drug Profiles - diphtheria tetanus toxoids acellular pertussis vaccine adsorbed combined with inactivated poliomyelitis vaccine - tetanus toxoid reduced diphtheria toxoid acellular pertussis vaccine adsorbed - DtwP-HB-Hib (liq) Vaccine - diphtheria tetanus pertussis (acellular) hepatitis B poliomyelitis (inactivated) haemophilus influenza polysaccharide conjugate [serogroup B] vaccine - GC-1107 - DTwP-HBV-Hib - VN-0103 - Hexavalent DTwP-Hepb-Hib-IPV Vaccine - Pentavalent DTwP-Hib-IPV Vaccine - GSK-217744 - TAK-361S - diphtheria tetanus pertussis vaccine - diphtheria tetanus pertussis (acellular) vaccine - diphtheria pertussis tetanus vaccine - diphtheria pertussis tetanus vaccine - Tetanus Vaccine - Toxoid Vaccine for Diptheria and Tetanus - Vaccine for Diptheria, Tetanus and Pertussis - Diptheria Tetanus Pertussis And Haemophilus Type B Conjugate Vaccine - GC-3111A - DTwP-IPV - DTaP Vaccine - Diphtheria Tetanus Pertussis (Acellular) Vaccine - DPT-H-HiB Vaccine - Tetanus Vaccine - tetanus vaccine - DTwP-Hep B-IPV-Hib - DTwP-IPV Hib - DTwP Hib For more information visit http://www.researchandmarkets.com/research/qnddk4/tetanus
GSK: 43.63 (+0.02), SVA: 5.34 (+0.01), NVS: 88.61 (+0.71)
Sinovac Announces New Presentation Time for Aegis Healthcare & Technology Conference
PR Newswire - Fri Sep 05, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced a new presentation time for the Aegis Healthcare & Technology Conference, to be held at the Wynn Las Vegas on September 12, 2014. Management will present at 8:00 am PT.
SVA: 5.34 (+0.01)
China Human Vaccine Industry Report, 2014-2017
M2 - Thu Sep 04, 9:57AM CDT
Research and Markets (http://www.researchandmarkets.com/research/sj5z5x/china_human) has announced the addition of the "China Human Vaccine Industry Report, 2014-2017" report to their offering. Chinese human vaccine market is still dominated by Beijing Tiantan Biological, Chengdu Institute of Biology under Chinese Academy of Sciences, Shanghai Institute of Biological Products Co., Ltd. , Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., Changchun Institute of Biological Products Co., Ltd., Institute of Medical Biology under Chinese Academy of Medical Sciences and other state-owned enterprises; but, their market share is falling. In 2013, the lot release volume of Chinese state-owned enterprises accounted for 69.9%, down 8.6 percentage points compared with last year; whereas, the share of private and foreign-funded enterprises jumped by 6 percentage points and 2.6 percentage points over the previous year respectively. The improved quality of Chinese vaccines, the increased export tax rebates (from 13% in 2009 to 15%) and other favorable factors have prompted China's human vaccine export volume and value to grow quickly. From January to June of 2014, the export volume and value amounted to 65.08 tons and USD15.45 million respectively, representing the separate increase of 115.6% and 50% over the same period of last year. As China's vaccine regulatory system is recognized by WHO, Chengdu Institute of Biology under Chinese Academy of Sciences, Beijing Tiantan Biological, Hualan Biological and other domestic vaccine companies are actively submitting pre-certification application to WHO in order to further expand overseas markets. In October 2013, the JE (Japanese encephalitis) vaccines of Chengdu Institute of Biology under Chinese Academy of Sciences were pre-certified by WHO at first and included in the procurement list of the United Nations. WHO inspected the influenza (split virion) vaccines of Hualan Biological on the spot in April 2014, and these vaccines are expected to be exported in 2015. Key Topics Covered: 1. Overview of Vaccine Industry 2. China Human Vaccine Industry & Market 3. Human Vaccine Market Segments in China 4. China's Import and Export of Vaccines 5. Major Vaccine Manufacturers in China - Beijing Tiantan Biological Products Co., Ltd - Changchun BCHT Biotechnology Co. Ltd. - Changchun Changsheng Life Sciences Limited - China National Biotec Group - Chongqing Zhifei Biological Products Co., Ltd - Dalian Hissen Bio-Pharm Co., Ltd - Hualan Biological Engineering Inc. - Liaoning Chengda Co., Ltd. - Shenzhen Kangtai Biological Products Co. Ltd - Sinovac Biotech Ltd. - Walvax Biotechnology Co., Ltd - Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd For more information visit http://www.researchandmarkets.com/research/sj...hina_human
SVA: 5.34 (+0.01)
Nasdaq stocks posting largest percentage decreases
AP - Wed Sep 03, 5:14PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
HELE: 60.25 (+1.40), RESN: 6.25 (-0.14), DHRM: 4.88 (+0.21), PACB: 5.56 (unch), PHII: 39.60 (-1.40), CONN: 31.07 (+1.31), RPRX: 6.02 (-0.21), DEPO: 14.86 (+0.15), PHIIK: 41.47 (+0.80), HMSY: 21.21 (+0.70), SVA: 5.34 (+0.01), DGLY: 12.99 (-0.15)
Sinovac Biotech Down 11.7% Since SmarTrend Downtrend Call (SVA)
Comtex SmarTrend(R) - Wed Sep 03, 9:24AM CDT
SmarTrend identified a Downtrend for Sinovac Biotech (AMEX:SVA) on April 15th, 2014 at $5.88. In approximately 5 months, Sinovac Biotech has returned 11.73% as of today's recent price of $5.19.
SVA: 5.34 (+0.01)
Sinovac to Participate in Upcoming Investor Conferences
PR Newswire - Tue Sep 02, 5:00AM CDT
Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the Company's management will participate in the following investor conferences in September:
SVA: 5.34 (+0.01), MS: 34.06 (+0.74)
Simavita Limited: Release of 2014 Financial Results
Marketwire - Thu Aug 28, 6:51PM CDT
Simavita Limited (ASX: SVA)(TSX VENTURE: SV) ("Simavita" or the "Company" is pleased to release its audited financial results and Management's Discussion and Analysis for the year ended June 30, 2014 available on SEDAR at www.sedar.ca. These year-end financials are the first such document produced by the Company since its re-listing on the TSX-V and its admission to the Official List of the ASX and includes financial information pertaining to its acquisition of Simavita Holdings Limited in December 2013.
SV.VN: 0.450 (+0.150), SVA: 5.34 (+0.01)